Low Expression of Mitochondrial Ribosomal Protein S5 is Associated With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma
Xiaoxiao Yang,Bo Han,Qian Xie,Yi Li,Qixuan Li,Xuelian Hu,Hongwen Zhao,Xiaosong Xu
DOI: https://doi.org/10.1097/pai.0000000000001236
IF: 1.992
2024-12-06
Applied Immunohistochemistry & Molecular Morphology
Abstract:Renal cell carcinoma (RCC), the most common malignant tumor of the kidney, arises from the renal tubular epithelial cells. 1 RCC is the second most malignant tumor of the urinary system after bladder cancer in China. 2 Globally, it is the seventh and ninth most common malignancy in males and females, accounting for 5% and 3% of all malignancies, respectively. 3 In recent years, the morbidity and mortality of RCC have been on the rise. One obvious phenomenon is that RCC has become a serious threat to human health. 4 Its pathologic subtypes mainly include clear cell RCC (ccRCC), papillary RCC, and chromophobe RCC. Among them, ccRCC is the most common one, accounting for 70% to 80% of all primary renal malignant tumors. 5 Due to the lack of typical clinical manifestations in the early stage, about 30% of patients have already developed distant metastasis at the time of initial diagnosis. 6–8 Although operation can radically resect the tumor tissue, up to 20% of patients have recurred or metastasized, postoperatively. 9,10 Furthermore, TNM stage and Fuhrman grade are widely used indicators for assessing the risk of recurrence and death. However, these indicators may not reliably predict the prognosis of patients - to a certain extent. 11 Therefore, it is of great practical significance to explore novel prognostic biomarkers for the disease.
pathology,medical laboratory technology,anatomy & morphology